Featured Research

from universities, journals, and other organizations

Rituximab Reduces Kidney Inflammation In Patients With Lupus

Date:
March 4, 2009
Source:
American Society of Nephrology
Summary:
Treatment with the targeted drug rituximab can significantly benefit some patients with severe lupus nephritis who do not respond to conventional therapy, according to a new study. The findings indicate that this immunosuppressive agent could improve the health of patients who have few other treatment options and who might otherwise develop end-stage renal disease.

Treatment with the targeted drug rituximab can significantly benefit some patients with severe lupus nephritis who do not respond to conventional therapy, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

Related Articles


The findings indicate that this immunosuppressive agent could improve the health of patients who have few other treatment options and who might otherwise develop end-stage renal disease (ESRD).

Lupus nephritis is a kidney disorder that arises in individuals who have the autoimmune disease systemic lupus erythematosus (SLE), and it puts individuals at elevated risk of developing ESRD. The standard treatment for lupus nephritis includes corticosteroids and cyclophosphamide, however a significant number of patients do not respond to these drugs or experience toxic effects when taking them. Because SLE seems to be caused at least in part by hyperreactive B cells of the immune system, targeting B cells could be a potential therapeutic option for patients with SLE and lupus nephritis.

A team of researchers led by Fadi Fakhouri, MD, of Imperial College in London, UK, recently tested the effects of rituximab—an antibody directed against B cells that was initially developed for the treatment of non-Hodgkin lymphoma—in patients with lupus nephritis. The study retrospectively assessed the long-term (≥12 months) efficacy and safety of rituximab in 20 SLE patients with severe lupus nephritis. After an average follow-up of 22 months, kidney improvements were seen in 12 patients (60%).

During the study, the investigators noted which patients benefited most from rituximab. They found a strong association between depletion of B cells after one month and treatment success. They found that patients with certain characteristics did not experience this beneficial B cell depletion and therefore might not be candidates for rituximab therapy. These characteristics included very low levels of albumin in the blood and black ethnicity.

The study's findings suggest that rituximab, which has low toxicity, could be an effective option for patients with lupus nephritis that is resistant to conventional therapy, particularly for those patients whose B cells become depleted after one month of treatment. "Prospective studies assessing the efficiency of rituximab, with or without cyclophosphamide, in severe lupus nephritis are warranted," the authors wrote.


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Catherine Melander, Marion Sallee, Pierre Trolliet, Sophie Candon, Xavier Belenfant, Eric Daugas, Phillipe Remy, Virginia Zarrouk, Evangeline Pillebout, Christian Jacquot, Jean-Jacques Boffa, Alexandre Karras, Virginie Masse, Phillippe Lesavre, Caroline Elie, Isabelle Brocheriou, Bertrand Knebelmann, Laure-Helene Noel, Fadi Fakhouri. Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome. Clinical Journal of the American Society Nephrology, 2009; DOI: 10.2215/CJN.04030808

Cite This Page:

American Society of Nephrology. "Rituximab Reduces Kidney Inflammation In Patients With Lupus." ScienceDaily. ScienceDaily, 4 March 2009. <www.sciencedaily.com/releases/2009/03/090304182103.htm>.
American Society of Nephrology. (2009, March 4). Rituximab Reduces Kidney Inflammation In Patients With Lupus. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2009/03/090304182103.htm
American Society of Nephrology. "Rituximab Reduces Kidney Inflammation In Patients With Lupus." ScienceDaily. www.sciencedaily.com/releases/2009/03/090304182103.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Breakfast Debate: To Eat Or Not To Eat?

Breakfast Debate: To Eat Or Not To Eat?

Newsy (Oct. 23, 2014) Conflicting studies published in the same week re-ignited the debate over whether we should be eating breakfast. Video provided by Newsy
Powered by NewsLook.com
Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Despite Rising Death Toll, Many Survive Ebola

Despite Rising Death Toll, Many Survive Ebola

AP (Oct. 23, 2014) The family of a Dallas nurse infected with Ebola in the US says doctors can no longer detect the virus in her. Despite the mounting death toll in West Africa, there are survivors there too. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins